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Abstract Eicosapentaenoic acid (EPA), but not its metabolites
(docosapentaenoic acid and docosahexaenoic acid), stimulated
nitric oxide (NO) production in endothelial cells in situ and
induced endothelium-dependent relaxation of bovine coronary
arteries precontracted with U46619. EPA induced a greater
production of NO, but a much smaller and more transient
elevation of intracellular Ca2+ concentration ([Ca2+]i), than did a
Ca2+ ionophore (ionomycin). EPA stimulated NO production
even in endothelial cells in situ loaded with a cytosolic Ca2+
chelator 1,2-bis-o-aminophenoxythamine-NP,NP,NP-tetraacetic
acid, which abolished the [Ca2+]i elevations induced by ATP
and EPA. The EPA-induced vasorelaxation was inhibited by Ng -
nitro-L-arginine methyl ester. Immunostaining analysis of
endothelial NO synthase (eNOS) and caveolin-1 in cultured
endothelial cells revealed eNOS to be colocalized with caveolin in
the cell membrane at a resting state, while EPA stimulated the
translocation of eNOS to the cytosol and its dissociation from
caveolin, to an extent comparable to that of the eNOS
translocation induced by a [Ca2+]i-elevating agonist (10 WM
bradykinin). Thus, EPA induces Ca2+-independent activation
and translocation of eNOS and endothelium-dependent
vasorelaxation. ß 2001 Federation of European Biochemical
Societies. Published by Elsevier Science B.V. All rights re-
served.
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1. Introduction
The dietary intake of large amounts of marine oils rich in
g-3 polyunsaturated fatty acids (PUFA) has been suggested
to account for the low incidence of coronary artery disease
among Greenland Eskimos [1]. Dietary supplementation
with ¢sh oil or eicosapentaenoic acid (EPA, C20:5n-3), a
PUFA of the g-3 series, augments endothelium-dependent
relaxations in porcine coronary arteries and also reduces
contractile responses evoked by noradrenaline and arachidon-
ic acid in the rat aorta [2^6]. In addition, chronic exposure
of cultured endothelial cells to EPA potentiates the release of
an endothelium-derived relaxing factor (nitric oxide, NO)
in response to receptor agonists, such as purines and kinins
[7].
Because NO production by the endothelium induces vaso-
relaxation and a reduction in platelet aggregation [8], it there-
fore has bene¢cial e¡ects for subjects with vascular diseases
[9^11]. Overcoming endothelial dysfunction by PUFA (espe-
cially EPA) contributes to a suppression of atherogenic pro-
cesses and of ischemic heart disease, whereas a recent random-
ized clinical trial showed that dietary intake of PUFA has
modest e¡ects on coronary atherosclerosis [12] and it was
also reported that docosahexaenoic acid (DHA), but not
EPA, has a blood pressure-lowering e¡ect in hyperlipidemic
men [13,14]. However, the cellular mechanism by which
PUFA potentiates endothelial function (NO production) has
remained to be clari¢ed. The direct e¡ects of PUFA on NO
production and intracellular Ca2 concentration ([Ca2]i) in
endothelial cells in situ have apparently never been docu-
mented. NO is synthesized from the amino acid L-arginine
by NO synthases (NOSs), comprised of Ca2-dependent con-
stitutive NOSs (endothelial and neuronal NOS) and Ca2-in-
dependent inducible NOS (iNOS) [15]. In unstimulated endo-
thelial cells, endothelial NOS (eNOS) is targeted to speci¢c
microdomains in the plasma membrane termed caveolae,
where eNOS is associated with a sca¡old protein caveolin,
resulting in tonic inhibition of the enzyme activity [16^20].
The elevation of [Ca2]i, induced by Ca2-elevating agonists
such as bradykinin (BK) and ATP, stimulates the binding of
calmodulin (CaM) to eNOS and the dissociation of the en-
zyme from caveolin, thereby activating eNOS [20]. In addition
to the Ca2-dependent activation of eNOS, Mizuno et al.
reported the agonist-dependent modulation of the relationship
between [Ca2]i and NO production in endothelial cells [21].
It was also reported that shear stress or ceramide can stim-
ulate NO production with no detectable increase in [Ca2]i in
endothelial cells [22,23], thereby indicating the Ca2-inde-
pendent activation of eNOS by these stimulations. However,
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Ca2-dependency of the PUFA-induced NO production in
endothelial cells has heretofore remained unknown.
Using endothelial cells in situ which only express the eNOS
isoform, instead of cultured endothelial cells which may also
possibly express Ca2-independent iNOS by stimulators in-
cluded in the growth medium, we examined e¡ects of PUFA
on [Ca2]i and NO production. We report here the ¢rst evi-
dence that EPA induces Ca2-independent activation and
translocation of eNOS in endothelial cells in situ, events
linked to endothelium-dependent vasorelaxation which was
blocked by a NOS blocker.
2. Materials and methods
2.1. Materials
EPA, docosapentaenoic acid (DPA), DHA, ATP and U-46619 were
purchased from Sigma (St. Louis, MO, USA). Fura-2/AM and 2,3-
diaminonaphthalene (DAN) were from Dojindo (Kumamoto, Japan).
1,2-Bis-o-aminophenoxythamine-NP,NP,NP-tetraacetic acid (BAPTA)/
AM was from Molecular Probes (OR, USA). Ng -Nitro-L-arginine
methyl ester (L-NAME) was from Wako Pure Chemical (Osaka, Ja-
pan), and 1-(2-tri£uoromethylphenyl) imidazole (TRIM) was from
Calbiochem (San Diego, CA, USA). All other chemicals were pur-
chased from Katayama Chemical (Osaka, Japan). The composition of
the normal physiological salt solution (PSS) was (in mM); 123 NaCl,
4.7 KCl, 15.5 NaHCO3, 1.2 KH2PO4, 1.2 MgCl2, 1.25 CaCl2 and 11.5
D-glucose. All solutions were gassed with a mixture of 5% CO2 and
95% O2 (pH adjusted to 7.4).
2.2. Measurement of [Ca2+]i of the endothelial cells in situ
The changes in [Ca2]i of the endothelial cells in situ were measured
using £uorometry of fura-2, as described [24^27]. Brie£y, the bovine
aortic valvular strips, obtained from a local slaughter-house, were
incubated in PSS containing 25 WM fura-2 AM for 90 min at 37‡C.
The £uorescence intensities at alternating 340 nm (F340) and 380 nm
(F380) excitation and their ratio (R = F340/F380) were monitored at
510 nm emission, using a spectro£uorometer (Hitachi F2000) which
operates on our own program [27]. Double staining of fura-2 and
£uorescent acetylated low-density lipoprotein revealed that fura-2 sig-
nals exclusively arose from the monolayered endothelial cells on the
surface of the aortic side of the aortic valves [24^27]. Before starting
the experimental protocol, all strips were stimulated with 10 WM ATP
for 1 min to obtain a reference response. The £uorescence ratio values
were normalized by assigning values in normal PSS and at the peak
response to 10 WM ATP to be 0 and 100%, respectively.
2.3. Measurements of NO production of the endothelial cells in situ
To determine NO production in endothelial cells in situ, we mea-
sured the concentration of nitrite in PSS, using a DAN assay, as
described [27]. PUFA was applied to the aortic valve pinned in the
Sylgard chamber by exchanging the solutions. At the end of the 5 min
treatment, the solution aspirated from the chamber was used for NO
measurements. To determine the basal NO production in endothelial
cells in situ at rest, fresh PSS (600 Wl) was applied to the aortic valve
for 5 min and was collected for NO measurements before the start of
the experiments.
The intensity of the £uorescent signal of 1-(H)-naphthotriazole, the
product of reactions between nitrite and DAN, was measured with
excitation at 365 nm and emission at 405 nm, using a spectro£uoro-
meter (Hitachi, F2000) with a detection limit of 10 nM. Standard
sodium nitrite solutions (10 nM^1 mM) were made fresh to obtain
a standard curve, before each measurement. The level of NO produc-
tion was expressed as a percentage, assigning value at the ‘zero’ level
( = background £uorescence of solution only, without the aortic
valves) and the value obtained from the aortic valves at rest (treated
with fresh PSS for 5 min) to be 0 and 100%, respectively.
2.4. Force recording of arterial strips with or without endothelium
Isometric contractions of the bovine coronary arterial rings without
adventitia, obtained from a local slaughter-house, were measured us-
ing a force transducer (TB-611T, Nihon-Kohden, Japan), as described
[25^27]. Brie£y, after recording steady responses to repeated applica-
tions of 118 mM K-depolarization, the e¡ects of PUFA on the force
were examined at the plateau phase of the sustained contraction in-
duced by 100 nM U-46619. The concentration of U-46619 (100 nM)
was selected to obtain the plateau phase of the sustained contraction
which is needed for the quantitative observation of the endothelium-
dependent vasorelaxation [26]. In some strips, the endothelium was
removed by rubbing with a cotton swab and complete removal of the
endothelium was con¢rmed by the absence of relaxation induced by
1 WM BK.
2.5. Cell culture and immunostaining
For confocal cell imaging studies, human cultured umbilical vein
endothelial cells (HUVEC; American Type Culture Collection) were
seeded onto a gelatin-coated cell disk (Sumitomo, Japan) and subcul-
tured for three to six passages. Immunocytochemistry of the serum-
deprived (24 h) HUVEC was done, as described previously [28]. The
cells were ¢xed with 4% paraformaldehyde for 10 min and subse-
quently permeabilized with 0.1% Triton X-100 and 0.1% bovine serum
albumin (BSA) for 5 min. After incubation with 10% BSA (1.5 h), the
cells were incubated with monoclonal mouse anti-eNOS (Transduc-
tion Laboratories) and rabbit anti-caveolin-1 (Santa Cruz Biotechnol-
ogy) antibodies at 1:100 dilution for 1.5 h. The cells were then in-
cubated with Cy-3-conjugated anti-mouse and Cy-2-conjugated anti-
rabbit antibodies at 1:500 dilution for 1.5 h. Immuno£uorescence
images of endothelial cells were observed under a confocal laser
scan microscope (LSM510, Zeiss).
To quantitatively analyze eNOS translocation, at least 100 cells on
each coverslip were evaluated for eNOS staining at the cell membrane
by an examiner who had been blinded to the culture conditions. The
proportion of cells exhibiting eNOS staining at the cell membrane was
quantitated for each experimental treatment: the data were expressed
as a percentage, assigning the value in the control cells (without stim-
ulation) to be 100%, as described previously [28].
2.6. Statistical analysis
The measured values were expressed as mean þ S.E.M. Student’s t-
test was used to determine the statistical signi¢cance between two
groups. An analysis of variance and multiple comparison test (Fisher’s
protected least signi¢cant di¡erence; PLAD) were used to determine
the statistical signi¢cance of the e¡ects of various concentrations of
the drugs. P-values 6 0.05 were considered to be signi¢cant.
3. Results
3.1. E¡ects of PUFA on [Ca2+]i elevation and NO production
of the endothelial cells in situ
Since eNOS is a Ca2/CaM-dependent enzyme, we ¢rst in-
vestigated e¡ects of PUFA on [Ca2]i levels in endothelial
cells in situ by comparison with a Ca2 ionophore, ionomycin
(ION), which simply elevates [Ca2]i without the activation of
any speci¢c signal transduction. As shown in Fig. 1A, ION
induced a sustained elevation of [Ca2]i. In contrast, EPA
induced a slight and transient elevation of [Ca2]i with no
detectable sustained elevation. Fig. 1B shows concentration-
dependent elevations of [Ca2]i induced by EPA and by ION.
60 WM EPA and 0.03 WM ION had the same degree of po-
tency in elevating [Ca2]i in endothelial cells in situ (Fig. 1B).
Other PUFA, EPA metabolites with a structure similar to that
of EPA (DHA and DPA), had no e¡ect on [Ca2]i levels (data
not shown), thereby supporting the speci¢city of EPA in in-
ducing the [Ca2]i elevations.
Fig. 2A shows the concentration-dependent elevation of
NO production induced by EPA. In contrast, only 0.3 WM,
but not 0.03 WM, ION potentiated NO production. DHA (up
to 60 WM) had no e¡ect on the NO production. DPA (60 WM)
unexpectedly and signi¢cantly inhibited NO production.
Since recent studies have suggested the presence of a Ca2-
independent activation of eNOS [21^23], we next examined
the relationship between NO production and [Ca2]i. EPA
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(30 and 60 WM) induced [Ca2]i elevation as much as or less
than seen with 0.03 WM ION (Fig. 1B), whereas 0.03 WM ION
caused no signi¢cant stimulation of NO production (Fig. 2A),
indicating that the extent of the EPA-induced [Ca2]i eleva-
tions is within subthreshold levels for the stimulation of NO
production. However, EPA markedly stimulated NO produc-
tion (Fig. 2A), thereby suggesting the involvement of Ca2-
independent NO production in the EPA-induced response.
Fig. 2B shows the relationship between [Ca2]i elevation (ab-
scissa) and NO production (ordinate). EPA concentration-de-
pendently shifted to the left and upward of the control curve
seen with ION stimulation, which suggested that EPA induces
Ca2-independent NO production.
3.2. E¡ect of PUFA on endothelium-dependent vasorelaxation
To determine the physiological role of NO released from
endothelial cells induced by PUFA, we examined the e¡ects of
PUFA on the contractility of rings of bovine coronary artery,
with and without the endothelium (Fig. 3). EPA (60 WM)
relaxed the bovine coronary artery precontracted with U-
46619 (a thromboxane A2 analogue): the force was decreased
to 20.6 þ 7.1% (n = 16; P6 0.01) of the U-46619-induced con-
traction ( = 100%) by EPA. The EPA-induced vasorelaxation
was inhibited either by the removal of the endothelium (Fig.
3B) or by an inhibitor for all isoforms of NOS (100 WM L-
NAME)[8] but not by a speci¢c inhibitor for iNOS (100 WM
TRIM) [29] (Fig. 3A): the EPA-induced relaxation
(18.9 þ 3.5% of the U-46619-induced contraction, n = 5) was
unchanged in the presence of TRIM (18.2 þ 6.5%, n = 5;
Ps 0.05) and decreased to 2.9 þ 7.6% (n = 5; P6 0.01) in
the presence of L-NAME. The presence of endothelium was
con¢rmed by the addition of 1 WM BK at the end of each
experiment. In contrast to EPA, DPA or DHA (up to 60 WM)
had no e¡ect on the contraction (data not shown), suggesting
that neither DPA nor DHA can induce endothelium-depen-
dent relaxation. These results suggest that EPA speci¢cally
induces endothelium-dependent vasorelaxation, which may
be mediated by NO released from endothelial cells in situ
through the activation of eNOS, but not of iNOS.
3.3. E¡ect of EPA on translocation of eNOS
Immunostaining of HUVEC using monoclonal eNOS and
caveolin-1 antibodies revealed a robust pattern of immuno-
£uorescence in resting cells (Fig. 4A); when primary antibody
was not used, there was no staining (data not shown). Cav-
eolin-1 and eNOS shared a similar and overlapping pattern of
distribution in endothelial cells, with staining for the two pro-
teins seen at the plasma membrane. Importantly, when endo-
thelial cells were treated with BK (1 WM, 15 min) or EPA (30
WM, 15 min), eNOS was translocated from the plasma mem-
brane to the cytosol, while caveolin-1 immunostaining was not
a¡ected (Fig. 4A). These results are compatible with the dis-
sociation of eNOS from caveolin-1 resident in the plasma
membrane, as induced by either BK or EPA. The extent of
the 60 WM EPA-induced translocation of eNOS was the same
as the extent of the eNOS translocation induced by 1 WM BK
(Fig. 4B).
3.4. E¡ect of BAPTA on production of NO induced by EPA
To determine if a slight and transient elevation of [Ca2]i
induced by EPA was required for the production of NO, we
investigated the e¡ect of chelation of cytosolic Ca2 on NO
Fig. 1. A: Representative recordings showing changes in [Ca2]i in-
duced by 10 WM ATP (as a reference), 0.3 WM ION and 60 WM
EPA. B: [Ca2]i elevation was expressed as a percentage, assigning
the value induced by 10 WM ATP to be 100%. Data were obtained
from four separate experiments and expressed as mean þ S.E.M.
**P6 0.01 versus ATP, 22P6 0.01 versus 0.3 WM ION.
Fig. 2. A: The extent of the NO production induced by PUFA and
ION. NO production was expressed as a percentage, assigning the
value obtained at rest ( = basal NO production by endothelial cells
in situ) to be 100% (n = 4). Data shown as mean þ S.E.M.
**P6 0.01 versus control, 2 P6 0.05 versus 0.3 WM ION and
22P6 0.01 versus 0.3 WM ION, respectively. B: Relationship be-
tween [Ca2]i elevation and NO production. The extent of [Ca2]i
elevation and NO production was normalized and expressed as a
percentage, as described in Section 2. Closed circle represents the
value obtained from the cells at rest.
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production in endothelial cell in situ, which were loaded with
fura-2 and a cytosolic Ca2 chelator, BAPTA. As shown in
Fig. 5A, neither ATP (10 WM) nor EPA (60 WM) can cause an
increase in [Ca2]i. The unresponsiveness to ATP or EPA is
not due to either cell toxicity or deterioration of fura-2 signal,
because a Ca2 ionophore, ION (5 WM), induced [Ca2]i ele-
vation although the rate of the [Ca2]i elevation was slower
than in the control (without BAPTA), such being compatible
with the chelation of cytosolic Ca2. In contrast, 60 WM EPA
stimulated NO production even in the BAPTA-loaded endo-
thelial cells in situ, to an extent comparable to that seen in
control cells (without BAPTA) (Fig. 5B). These results suggest
that EPA stimulates NO production with no detectable
[Ca2]i elevation in endothelial cells in situ.
4. Discussion
The novel ¢ndings of this study are that EPA induces Ca2-
independent activation of eNOS and the translocation and
dissociation from caveolin-1 of eNOS in endothelial cells in
situ, which express only eNOS, but not Ca2-independent
iNOS. EPA-induced NO production is linked to physiological
functions, namely endothelium-dependent vasorelaxation.
This is also the ¢rst report to demonstrate rapid and direct
e¡ects of EPA not only on NO production and [Ca2]i but
also their relationships in endothelial cells in situ, although
there is documentation on the bene¢cial e¡ects of either diet-
ary supplementation with PUFA or chronic exposure to
PUFA on endothelial dysfunction and on abnormal vascular
contractions induced by vasospastic agonists [2^7] and a re-
cent study is rather controversial and shows that DHA, but
Fig. 3. Representative recordings showing e¡ects of 60 WM EPA on
contractions of the bovine coronary artery, with (A) and without
(B) endothelium, precontracted by 100 nM U-46619.
Fig. 4. Translocation and dissociation from caveolin-1 of eNOS in
endothelial cells in response to BK and EPA (15 min). A: Represen-
tative confocal images showing the immunostaining of eNOS (la-
beled with Cy-3) and caveolin-1 (labeled with Cy-2) and overlay
view of both in endothelial cells which were stimulated by 1 WM
BK and 30 WM EPA. B: The extent of the translocation of eNOS
in endothelial cells induced by 1 WM BK and 30 and 60 WM EPA.
The proportion of cell with eNOS staining at the cell membrane
was determined, as described in Section 2. The data represent the
mean þ S.E.M. derived from six independent culture preparations.
**P6 0.01 versus control.
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not EPA, reduces ambulatory blood pressure in mildly hyper-
lipidemic men [13] and stimulates vasodilator response and
inhibits constrictor response in the forearm microcirculation
[14].
To explore Ca2-dependency in the activation of eNOS
while avoiding possible interference by the Ca2-independent
activity of iNOS, we used endothelial cells in situ, which ex-
press only eNOS, but not iNOS [27], instead of using cultured
endothelial cells which are grown in the presence of several
growth factors included in the medium that may possibly
stimulate the induction of iNOS. In the present study, we
proposed the Ca2-independent activation of eNOS by EPA,
based on the following evidence: (1) the extent of the 60 WM
EPA-induced [Ca2]i elevation was comparable to the extent
of 0.03 WM ION which is a subthreshold level of [Ca2]i for
NO production (Fig. 1); (2) the extent of NO production
induced by EPA was much larger than that expected from
the extent of the EPA-induced [Ca2]i elevation, as compared
with stimulation with a Ca2 ionophore ION (Fig. 2B);
(3) the chelation of cytosolic Ca2with BAPTA abolished
the [Ca2]i elevations induced by EPA or ATP. However,
EPA still stimulated NO production even after the chelation
of cytosolic Ca2 (Fig. 5). (4) EPA induced transient elevation
of [Ca2]i without the sustained elevation (Fig. 1A). These
observations also support the Ca2-independent activation
of eNOS, because sustained elevation of [Ca2]i, but not tran-
sient elevation of [Ca2]i, plays a major role in the Ca2-de-
pendent activation of eNOS [30]. However, the involvement of
fura-2-undetectable and BAPTA-insensitive Ca2 pools was
not ruled out in the present study. Further experiments are
required to obtain more conclusive results: for example, it
may be helpful to show the di¡erential sensitivity to BAPTA
between EPA and BK responses.
It is unlikely that the Ca2-independent activity of iNOS is
involved in the observed Ca2-independent NO production by
EPA, for the following reasons: (1) the EPA-induced endo-
thelium-dependent vasorelaxation was interfered with by an
inhibitor for both eNOS and iNOS (L-NAME), but not by a
selective inhibitor of iNOS (TRIM) (Fig. 3); (2) Western blot
analysis showed that endothelial cells in situ used in the
present study expressed only eNOS, not iNOS, and (3) the
rapid response to EPA is not compatible with the de novo
induction of iNOS.
The e¡ects of EPA are speci¢c, because its metabolites
(DPA and DHA) with a structure similar to that of EPA
had no e¡ect on [Ca2]i elevation, NO production or vascular
contraction. However, the molecular mechanisms by which
EPA stimulates NO production and translocation of eNOS
remain unknown. The following two possibilities may account
for the EPA action on eNOS. (1) It was recently reported that
EPA inhibits the palmitoylation of Src family kinase such as
Fyn and the kinase translocation to detergent-resistant micro-
domains of the cell membrane (probably caveolae) [31]. En-
dothelial NOS is also both myristoylated and palmitoylated
[28,32^34]. The acylation of eNOS is required for targeting of
the enzyme to caveolae [35]. It was reported that eNOS pal-
mitoylation is dynamically regulated and the agonist-induced
depalmitoylation of the enzyme results in its translocation to
the cytosol [36]. Therefore, EPA may inhibit the palmitoyla-
tion of eNOS and its targeting to caveolae and caveolin, the
result being eNOS translocation to the cytosol and thereby
activation of the enzyme, in a Ca2-independent manner.
(2) It is well documented that caveolin blocks eNOS activity
by its association with the enzyme in caveolae [17,20].
Caveolin is also a fatty acid (FA)-binding protein and has
an important role in FA transport between membrane com-
partments [37,38]. Because EPA is also a FA, it is likely that
EPA can bind to caveolin, which may in turn assist caveolin
to associate with eNOS and thereby activate the eNOS activ-
ity. However, in this case, it is still unclear why EPA may
activate eNOS and its closely-related metabolites (DPA and
DHA) do not.
In conclusion, this is the ¢rst documentation that EPA in-
duces Ca2-independent activation and translocation of eNOS
and endothelium-dependent vasorelaxation. It is possible that
EPA may be actively incorporated into membrane phospho-
lipid and therefore the free pool as a free fatty acid (FFA)
fraction may be rather small. However, the concentration (30
and 60 WM) of EPA used in the present study seems to be
physiological, since it was reported that the plasma concen-
tration of EPA in a FFA fraction is 39.4 and 280 WM in
healthy and diabetic human subjects, respectively [39,40].
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